A scientific seminar on "HER2-HER3 positive breast and lung cancer, therapy of brain metastases" will be held at the Institute of Biophysics

On November 6, 2024, at 11:00 AM, an academic seminar titled "Therapy of HER2-HER3 Positive Breast and Lung Cancer and Brain Metastases" will be held at the BioPhysics Institute of the Ministry of Science and Education of the Republic of Azerbaijan. Sevda Mahmudova, a junior researcher from the Laboratory of Molecular and Cellular Biochemistry, will present at the seminar.

You are kindly invited to attend the seminar.

Brief Information:

HER2, encoded by a gene located on the short arm of chromosome 17 (q22), is a member of the human epidermal growth factor receptor family. Developing drugs that target the HER2 signaling pathway and overcoming drug resistance is crucial for the treatment of HER2+ breast cancer (as well as lung carcinoma). The survival rate of breast cancer patients is determined by several clinical factors, including the stage and grade of the tumor, the status of estrogen and progesterone receptors, as well as HER2 status. Overexpression of the HER2 protein, one of these factors, indicates a poor prognosis for patients. Brain metastases develop in up to 30%-50% of breast cancer patients, significantly affecting their survival and quality of life. Monoclonal antibodies and tyrosine kinase inhibitors are widely used in the treatment of brain metastases and breast cancer.

01 November 2024

Share